Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data
European Journal of Neurology · 2026
DOI: 10.1111/ene.70568 ↗At a glance
Journal article in European Journal of Neurology, 2026. Written by Loredana Storelli and 7 co-authors. Institution: Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. Major MEDLINE topics: Multiple Sclerosis, Deep Learning, Artificial Intelligence, Cognitive Dysfunction. Cited 3 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Fondazione Italiana Sclerosi Multipla.
Abstract (original language)
Background
Cognitive impairment is common in multiple sclerosis (MS), yet the application of diagnostic frameworks of Neurocognitive Disorders (NCDs) is limited. Additionally, the integration of multimodal data for predicting cognitive outcomes using artificial intelligence (AI) remains underexplored. This study aimed to characterize NCDs in MS and predict cognitive worsening using an explainable deep learning model trained on MRI and clinical data.
Methods
Two‐hundred twenty‐four MS patients and 115 healthy controls (HC) underwent 3.0 T MRI and clinical assessment at baseline. MS patients also completed neuropsychological testing, including estimation of z‐cognitive reserve, at baseline and after a median follow‐up of 3.4 (interquartile range = [2.0; 6.1]) years. MS patients were classified as Mild or Major NCD according to the Diagnostic and Statistical Manual of Mental Disorders criteria at baseline, and as “stable” or “worsened” based on cognitive changes at follow‐up. A deep learning model was trained on baseline T1‐weighted MRI, demographic, clinical, and brain volumetric data to predict cognitive decline, with explainability methods used to interpret the model's decisions.
Results
At baseline, 4% of patients had Mild and 11% Major NCD. At follow‐up, 12% showed cognitive decline. The deep learning model predicted follow‐up cognitive status with 90% accuracy. Explainability models identified the most relevant predictors, in order of importance: cortical gray matter volume, age, thalamic and hippocampal volumes, T2 lesion volume, and z‐cognitive reserve.
Conclusions
The proposed multimodal AI approach demonstrated robust performance and highlighted relevant brain regions associated with cognitive worsening, underscoring its potential for personalized cognitive assessment and monitoring in MS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy.
ORCID profiles: Maria A Rocca
Funding
- Fondazione Italiana Sclerosi Multipla
Cite
APA
Storelli, L., Mistri, D., Mastropasqua, A., Grosselle, M., Preziosa, P., Rossi, L., Filippi, M., & Rocca, M. A. (2026). Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data. European Journal of Neurology. https://doi.org/10.1111/ene.70568
Vancouver
Storelli L, Mistri D, Mastropasqua A, Grosselle M, Preziosa P, Rossi L, et al. Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data. European Journal of Neurology. 2026. doi:10.1111/ene.70568
BibTeX
@article{Storelli2026,
author = {Storelli, Loredana and Mistri, Damiano and Mastropasqua, Alice and Grosselle, Marta and Preziosa, Paolo and Rossi, Lucrezia and Filippi, Massimo and Rocca, Maria A},
title = {Explainable Artificial Intelligence to Predict Neurocognitive Disorder Progression in Multiple Sclerosis Using MRI and Clinical Data},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70568}
}
EUVIMED